Importance of the Study
The study provides detailed insights on the role of the Angiotensin-converting enzyme (ACE) inhibitors in minimizing the morbidity and morality in patients suffering from chronic heart failure and those who have been exposed to acute myocardial infarction (AMI) (Dickstein 766). It includes a critical analysis on the role of ACR in conventional therapy among patients and analysis of the demographics in relation to their reaction to the ACE inhibitors.
Primary Hypothesis: Treatment with Losartan in selected, high-risk patients after AMI, would help in the reduction of all cause morality as compared to Captopril.
Secondary Hypothesis: Treating patients with Losartan has reduced Cardiac deaths and fatal reinfarction incidences.
Clinically stable patients of all genders, aged above 50 years, were eligible to participate in the study. The inclusion criteria encompassed patients who were either under-treatment of heart failure, pulmonary rates, or their heat sound. The sample size calculation was grounded on the demonstration of losartan superiority.
Findings and Interpretation
In the first seven days of the study, 7.4 % of the patients had cases of hypertension and none of the cases were severe. In the first 30 days, 6.2% of the participating patients had a downward titration of the medication does, where 5.8 % of the patients withdrew from the study medication. By the 270th day, 81.3% of the patients were on the target dose, whereas 12.7% of them had abandoned the study medication. Some of the most adverse effects experienced during the study included dizziness and serum creatinine. There were also reported cases of cardiovascular and sudden deaths, where heart failure was the leading cause of the mortality risks during the time interval.
Dickstein, Kenneth, and John Kjekshus. “Comparison of baseline data, initial course, and management: Losartan versus captopril following acute myocardial infarction (The OPTIMAAL trial).” American Journal of Cardiology 87.6 (2001): 766-771.